Complete remission (no further aphthous episodes to 6 months) · idiopathic steroid‐resistant nephrotic syndrome in children
IV cyclophosphamide showed no clear difference in treatment response at 6 months: complete remission compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
1 finding from 1 review
Treatment response at 6 months: partial remission · idiopathic steroid‐resistant nephrotic syndrome in children
IV cyclophosphamide showed no clear difference in treatment response at 6 months: partial remission compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
1 finding from 1 review
Complete or partial remission · idiopathic steroid‐resistant nephrotic syndrome in children
IV cyclophosphamide showed no clear difference in treatment response at 6 months: complete or partial remission compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
1 finding from 1 review
Treatment response at 18 months ‐ Sustained remission/steroid sensitive relapses Clinical assessment · idiopathic steroid‐resistant nephrotic syndrome in children
IV cyclophosphamide showed no clear difference in treatment response at 18 months: sustained… compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
1 finding from 1 review
Treatment response at 18 months ‐ CKD clinical assessment · idiopathic steroid‐resistant nephrotic syndrome in children
IV cyclophosphamide showed no clear difference in treatment response at 18 months: CKD compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
1 finding from 1 review
Adverse events: hypertension · idiopathic steroid‐resistant nephrotic syndrome in children
IV cyclophosphamide may leads to lower adverse events: hypertension compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
1 finding from 1 review
Adverse effects ‐ Bacterial infection clinical assessment · idiopathic steroid‐resistant nephrotic syndrome in children
IV cyclophosphamide showed no clear difference in adverse events: bacterial infections compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
1 finding from 1 review